Modner: In a few weeks, you can start research and development of additional additions

(Zurich Lainer) American pharmaceutical dealer Modner said that he is capable of developing vaccine additions for Omikdon, and research and development work is expected to be launched within a few weeks.

Moderner President Bancele said that Modner hopes to start clinical trials on Omikon's vaccine starting early next year, but the company is currently concentrating on development to cope with Omikon RongAdding agent.

Tages-Anzeiger reported on the 21st that Bancele said that the additional agent "only needs to be slightly adjusted for the Omikon strain, and I don't think there will be any problems."

If the official approval is three months, it takes three months

Modner is currently waiting for important information about this variant to start development.Bancer said: "This takes a week or two."

He also said: "Once (once the regulatory agency) is approved, we need a few months to produce a 500 million doses of additional doses. Our production capacity today is much higher than a year ago. "

The production capacity will increase next year to 150 million doses

He said, if American foodFor further research with the request for approval agencies such as the Drug Administration and the Swiss medical institution, it takes at least three months to take at least three months."Some regulatory agencies need to be further studied, and some have not made decisions. According to my opinion, this depends to a large extent on the degree of worsening of the epidemic."

After the delivery delay and production lag of production earlier this year,Modner is now able to keep up with production targets and deliver them on time.The company produces 700 million to 800 million vaccines this year, and is expected to increase production capacity next year, increasing production from 100 million doses to 150 million doses per month.

Bancele said that other production lines built by the company and Lonza, a Swiss pharmaceutical dealer, will be put into operation in the first quarter of next year to increase output.

He added that the company had 30 million doses of inventory for the first time.